Invention Grant
US09206481B2 Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
有权
前列腺癌特异性改变ERG基因表达和基于这些改变的检测和治疗方法
- Patent Title: Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
- Patent Title (中): 前列腺癌特异性改变ERG基因表达和基于这些改变的检测和治疗方法
-
Application No.: US12081101Application Date: 2008-04-10
-
Publication No.: US09206481B2Publication Date: 2015-12-08
- Inventor: Shiv Srivastava , Albert Dobi , Taduru Sreenath , Gyorgy Petrovics , Chen Sun
- Applicant: Shiv Srivastava , Albert Dobi , Taduru Sreenath , Gyorgy Petrovics , Chen Sun
- Applicant Address: US MD Bethesda
- Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Current Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Current Assignee Address: US MD Bethesda
- Agency: MH2 Technology Law Group, LLP
- Main IPC: C12Q1/68
- IPC: C12Q1/68
Abstract:
Alterations in ERG gene expression can be observed in patients with prostate cancer. Specific ERG isoforms are associated with, or involved in, prostate cancer. Compositions comprising these isoforms provide therapeutic benefit and can be used in methods of detecting, diagnosing, prognosing, and treating prostate cancer. These compositions provide biomarkers for detecting the expression of combinations of the PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG genes.
Public/Granted literature
Information query
